Full-Time
Senior – Business Application Engineer
Polarion ALM
Posted on 8/19/2026
Brainlab
1,001-5,000 employees
Medical software and hardware for surgeries
No salary listed
Munich, Germany
Hybrid
Hybrid work model within Germany.
Bachelor's
 Software Engineering (1) |
|---|
Get referred to Brainlab
See people who can refer or advise you
- Education in Engineering, Information Technology, Computer Science, or equivalent professional experience.
- Experience with Polarion ALM configuration, customization, administration, and support.
- Experience with Java and/or JavaScript.
- Proficiency in English.
- Collaborate with business stakeholders to identify technical opportunities and gather user requirements for Polarion customizations, workflows, reports, dashboards, and integrations.
- Configure, customize, and maintain Polarion ALM solutions to support engineering, quality, and compliance processes.
- Perform troubleshooting and provide user support to ensure reliable system operation and high user satisfaction.
- Perform system administration tasks, including user, role, and permission management; system monitoring and health checks; log-file analysis and troubleshooting; upgrades, patching, and validation; and performance analysis and optimization.
- Develop and maintain technical documentation, system configurations, operating procedures, and user training materials.
- Support validation, change management, and compliance activities in regulated environments.
- Collaborate with process engineers and business stakeholders to continuously improve processes and system capabilities.
- Experience with REST APIs, SQL databases, Git, and modern development tools.
- Experience with the Polarion SDK, Velocity scripting, and system integrations.
- Experience with Application Lifecycle Management, Requirements Management, Test Management, or regulated development processes.
- German proficiency.
- Strong communication and stakeholder management skills.
- Creativity, logical and structured thinking, and a passion for solving complex technical and business challenges.
Brainlab is a medical technology company that creates software and hardware to improve surgeries, radiosurgery treatments, and operating room efficiency. It serves hospitals and clinics by providing digital tools that enhance surgical precision and patient outcomes. The core products include image-guided navigation, planning software, and connected hardware that work together to guide procedures. Revenue comes from selling software licenses, hardware devices, and ongoing subscription services that include updates and support. The company differentiates itself by offering integrated digital medical technologies that combine software and hardware for a seamless clinical workflow, backed by service agreements. Its goal is to help healthcare providers perform safer, more accurate procedures and run operating rooms more efficiently through data-driven tools and ongoing support.
Company Size
1,001-5,000
Company Stage
Early VC
Total Funding
$7.3M
Headquarters
Munich, Germany
Founded
1989
Get referred to Brainlab
See people who can refer or advise you
Simplify's Take
What believers are saying
- Brainlab grew 2024/25 revenue 6.8% to €492.5 million and kept hiring.
- July 2026 KIMS Bengaluru became South Asia's first Brainlab functional neurosurgery reference center.
- February 2026 Precision NeuroMed partnership opens a new AI drug-delivery planning market.
What critics are saying
- Brainlab canceled its July 2025 Frankfurt IPO; private-capital dependence persists through August 2026.
- Precision NeuroMed and Nexstim tie capital to clinical bets that can miss regulatory timelines.
- Siemens Healthineers, Medtronic, and Elekta can bundle broader platforms and squeeze Brainlab margins.
What makes Brainlab unique
- Brainlab spans planning, navigation, imaging, and OR workflow across 4,000 hospitals.
- Its FDA-cleared mixed reality spine navigation deepens surgeon-facing visualization beyond standard optical systems.
- Brainlab pairs software with hardware, creating sticky installed workflows and recurring service revenue.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Flexible Work Hours
Paid Vacation
Paid Holidays
Conference Attendance Budget
Professional Development Budget
Wellness Program
Mental Health Support
Stock Options
Company Equity
401(k) Retirement Plan
401(k) Company Match
Phone/Internet Stipend
Home Office Stipend
Health Insurance
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↓ -1%2 year growth
↑ 0%Finnish medical technology company Nexstim has registered 502,500 new shares with the Finnish Trade Register following investments from Eiffel Investment Group and Brainlab SE. Eiffel invested €3.4 million for 446,459 shares, whilst Brainlab invested €0.4 million for 56,041 shares. Additionally, Eiffel exercised 263,091 option rights and other option holders exercised 74,372 option rights, resulting in 337,463 new shares being registered. The new shares began trading on Nasdaq First North Growth Market Finland alongside existing shares. Following the registrations, Nexstim's total share count stands at 8,074,859. The company develops navigated transcranial magnetic stimulation technology for brain diagnostics and therapy, with FDA-cleared systems for pre-surgical brain mapping and treating major depressive disorder.
Finnish medical technology company Nexstim has registered 840,000 new shares with the Finnish Trade Register following recent investments and option exercises. The company issued 502,500 shares to Eiffel Investment Group (€3.4 million) and Brainlab SE (€0.4 million), registered on 18 May and trading from 20 May. Additionally, 337,463 shares were issued through option exercises, including 263,091 by Eiffel and 74,372 by existing option holders, registered on 22 May and trading from 25 May. Following these registrations, Nexstim's total share count stands at 8,074,859. The company develops navigated transcranial magnetic stimulation technology for brain diagnostics and therapy, with its NBS System 6 FDA-cleared for pre-surgical brain mapping and treating major depressive disorder and obsessive compulsive disorder.
Company Announcement, Helsinki, 13 May 2026 at 09:05 AM (EEST) Inside Information: Nexstim Plc Announces EUR 5 Million Investment from Eiffel and from Brainlab and Conversion of Options by Certain Option
AB S.A., a Polish healthcare technology company, has secured €5 million in investment from Eiffel Investment Group and Brainlab. The funding coincides with option conversions by certain holders, strengthening the company's financial position. AB S.A. operates in the healthcare technology sector, providing software solutions including electronic health records, practice management systems and telehealth platforms for medical practices and laboratories. The company generates revenue through subscription-based software and services, primarily serving markets across Poland and Europe. The investment signals investor confidence in AB S.A.'s growth prospects within the European healthcare IT sector. The capital will support product development and market expansion efforts as the company benefits from ongoing digitalisation trends in European healthcare.
Brainlab and Precision NeuroMed have formed a strategic partnership to develop an AI-enabled treatment planning platform for convection enhanced delivery (CED) to the brain. Brainlab has taken an equity stake in the clinical-stage biotechnology company as part of the collaboration. The partnership aims to create a cloud-based CED Treatment Planning System that combines Brainlab's medical imaging expertise with Precision NeuroMed's molecular flow simulation software. The platform will use advanced imaging and AI-driven optimisation to personalise drug distribution, overcoming blood-brain barrier limitations that restrict most systemically administered drugs. Initial development will focus on supporting Precision NeuroMed's lead drug, PNM-201, for recurrent glioblastoma. The companies plan to expand the platform to enable delivery of therapies for epilepsy, Parkinson's disease, Alzheimer's disease and ALS.